Roche’s antibody cocktail launched in India at ₹59,750/dose
PTI
New Delhi |
Updated on
May 24, 2021
Cipla to market drug in country
Drug majors Roche India and Cipla on Monday announced launch of Roche's Antibody Cocktail in India priced at ₹59,750 per dose for the treatment of mild to moderate Covid-19 in patients who are at high risk.
“The first batch of the Antibody Cocktail (Casirivimab and Imdevimab) is now available in India while a second batch will be made available by mid-June. In total they can potentially benefit 2,00,000 patients as each of the 1,00,000 packs that will be available in India offers treatment for two patients," Cipla and Roche said in a joint statement. Cipla will distribute the product by leveraging its strong distribution strengths across the country, it added.